145 related articles for article (PubMed ID: 38242326)
1. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
Espinoza AF; Patel RH; Patel KR; Badachhape AA; Whitlock R; Srivastava RK; Govindu SR; Duong A; Kona A; Kureti P; Armbruster B; Kats D; Srinivasan RR; Dobrolecki LE; Yu X; Najaf Panah MJ; Zorman B; Sarabia SF; Urbicain M; Major A; Bissig KD; Keller C; Lewis MT; Heczey A; Sumazin P; López-Terrada DH; Woodfield SE; Vasudevan SA
J Hepatol; 2024 Apr; 80(4):610-621. PubMed ID: 38242326
[TBL] [Abstract][Full Text] [Related]
2. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
Lachenmayer A; Toffanin S; Cabellos L; Alsinet C; Hoshida Y; Villanueva A; Minguez B; Tsai HW; Ward SC; Thung S; Friedman SL; Llovet JM
J Hepatol; 2012 Jun; 56(6):1343-50. PubMed ID: 22322234
[TBL] [Abstract][Full Text] [Related]
4. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
6. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
7. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
10. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG; Laubach JP; Richter J; Stricker S; Spencer A; Richardson PG; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):752-765. PubMed ID: 34340951
[TBL] [Abstract][Full Text] [Related]
12. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
14. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
15. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
[TBL] [Abstract][Full Text] [Related]
16. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
18. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
20. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
